Research

Research
Rengalin
Rengalin® is a treatment for non-productive and productive cough in adults and children from 3 years of age.
15 Researches

Rengalin

Rengalin® is a treatment for non-productive and productive cough in adults and children from 3 years of age.
Information about the preparation

Study report. Non-clinical safety study of complex drug containing ULD of antibodies. Study of allergenic and local irritating properties, (2009), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of complex drug containing ULD of antibodies. Effect of the drug containing ULD of antibodies administered to females during lactation on posterity development, (2009), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of complex drug containing ULD of antibodies. Study of immunotoxic properties, (2009), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of complex drug containing ULD of antibodies. Изучение кумуляции, (2009), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of complex drug containing ULD of antibodies. Study of mutagenic activity, (2009), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of complex drug containing ULD of antibodies. Изучение острой токсичности, (2009), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of complex drug containing ULD of antibodies. Effect of the drug containing ULD of antibodies. Reproductive toxicity study: effect on reproductive function of rats, (2009), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of complex drug containing ULD of antibodies. Chronic toxicity study on sexually immature rats, (2009), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of complex drug containing ULD of antibodies. Chronic toxicity study on rabbits, (2009), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of complex drug containing ULD of antibodies. Chronic toxicity study on rabbits, (2009), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of complex drug containing ULD of antibodies. Study of embryo- and fetotoxic effect of drug containing ULD of antibodies in antenatal and postnatal development periods, (2009), Volgograd, Russia, Volgograd State Medical University. Final report Study of neurophysiologic mechanisms of narcogenic potential of the drugs containing low doses of antibodies, (2010), Kharkov, Ukraine, Institute of Neurology, Psychiatry and Narcology, Academy of Medical Sciences of Ukraine. Report. Study of antitussive properties of the drugs containing ULD of antibodies on the model of cough induced by respiratory administration of capsaicin in guinea pigs, (2012), Tomsk, Russia, RI of Pharmacology. In vitro study of antibodies to histamine in release-active form: effect on functional activity of H4 histamine receptor, (2014), Belgium, Euroscreen. Study report. Study of efficacy of the drug manufactured by OOO “NPF “Materia Medica Holding” Rengalin on the model of experimental IgE-dependent bronchial asthma, (-), Moscow, Russia, Institute of Immunology.
Ergoferon
Ergoferon® has an enhanced potency owing to the combination of antiviral, anti-inflammatory and antihistamine effects.
21 Researches

Ergoferon

Ergoferon® has an enhanced potency owing to the combination of antiviral, anti-inflammatory and antihistamine effects.
Information about the preparation

Efficacy of MATERIA MEDICA samples in ovalbumin-induced bronchial asthma complicated with rhinovirus in vivo (Imperial College Consultants Ltd, Great Britain, Sebastian L Johnston), 2012 Study of antiviral activity of MMH drugs on in vitro model of respiratory syncytial virus infection (RSV) and infection caused by vesicular stomatitis virus (VSV) (Institute of Immunology, Russia, Khaitov M.R.), 2011 Study of therapeutic and preventive efficacy of the drugs manufactured by OOO “NPF “Materia Medica Holding” vs. oseltamivir in mice contaminated intranasally with A/Aichi/2/68 (H3N2) influenza strain, Vektor, 2013 Experimental study of activity of Ergoferon manufactured by OOO “NPF “Materia Medica Holding” on the models of carrageenan-induced paw edema and formalin inflammation in rats, Tomsk, 2013 The influence of Ergoferon, manufactured by OOO "NPF "MATERIA MEDICA HOLDING", on histamine ability to activate contractions of lung strips by activation of H1-histamine receptors, Eurofins, 2014 Study of antiviral activity of MMH drugs on in vitro model of infection caused by respiratory syncytial virus, Institute of Immunology, 2014 Study of antiviral activity of Ergoferon  on experimental in vitro model of infection caused by rotavirus A,  Institute of Immunology, 2015 Study report. Study of the drugs manufactured by OOO “NPF “Materia Medica Holding” on the model of experimentally induced IgE-dependent bronchial asthma in vivo" (RF, Moscow, Institute of Immunology, RAMS, 2013) Study report “Non-clinical safety study of Ergoferon. Single dose toxicity (Volgograd State Medical University, Russia (Volgograd, Russia), 2011) Study report Non-clinical safety study of Ergoferon. Chronic toxicity study on rats (Volgograd State Medical University, Russia (Volgograd, Russia), 2012) Study report “Non-clinical safety study of complex drug Ergoferon. Chronic toxicity study on sexually mature rats (Volgograd State Medical University, Russia (Volgograd, Russia), 2011) Study report “Non-clinical safety study of Ergoferon. Chronic toxicity study on rabbits” (Volgograd State Medical University, Russia (Volgograd, Russia), 2012) Study report Non-clinical safety study of Ergoferon. Mutagenic activity  study” (Volgograd State Medical University, Russia (Volgograd, Russia), 2011) Study report Non-clinical safety study of Ergoferon. Reproductive toxicity study: effect on reproductive function of rats” (Volgograd State Medical University, Russia (Volgograd, Russia), 2011) Study report Non-clinical safety study of Ergoferon. Study of embryo- and fetotoxic effect of the drug in antenatal and postnatal development periods (Volgograd State Medical University, Russia (Volgograd, Russia), 2011) Study report Non-clinical safety study of Ergoferon. Effect of Ergoferon administered to lactating females on posterity development  (Volgograd State Medical University, Russia (Volgograd, Russia), 2011) Study report Non-clinical safety study of Ergoferon. Study of allergenic and local irritating properties” (Volgograd State Medical University, Russia (Volgograd, Russia), год) Study report Non-clinical safety study of Ergoferon. Study of immunotoxic properties (Volgograd State Medical University, Russia (Volgograd, Russia), 2011) Study report Experimental study of the effect of the drugs manufactured by OOO “NPF “Materia Medica Holdign” on delayed-type hypersensitivity in sheep erythrocyte sensitization  (RF, Tomsk, RI of Pharmacology, RAMS, 2013) Study report Non-clinical safety study of Ergoferon. Accumulation study (Volgograd State Medical University, Russia (Volgograd, Russia), 2011) Clinicaltrials
Tenoten for children
Tenoten for children® is the only anti-anxiety drug designed specifically for pediatric patients taking in account the peculiarities of children's mental health.
14 Researches

Tenoten for children

Tenoten for children® is the only anti-anxiety drug designed specifically for pediatric patients taking in account the peculiarities of children's mental health.
Information about the preparation

Report Non-clinical safety study of Tenoten for children. Study of immunotoxic properties, (2008), Volgograd, Russia, Volgograd State Medical University In vitro study of ultralow doses of antibodies to S100 protein using radioligand binding assay: sigma 1 receptor, ММЕ-001 (2009),  Gosselies, Belgium, Euroscreen S.A. In Vitro Pharmacology: Study of OOO “NPF”MATERIA MEDICA HOLDING” Samples in σ 1 Receptor Binding Assay, Non-Selective σ Receptor Bioassay, and NO Synthases Enzyme Assays, (2011), Le Bois l’Evêque, France, Cerep. Report Study of protective effect of Tenoten for children of Tenoten for children on the model of experimentally induced allergic encephalomyelitis in rats, (2011), Saint-Petersburg, Russia, RI of Experimental Medicine, North-Western Department, RAMS Report Study of general toxic properties of Tenoten for children. Acute toxicity toxicity (2008), Volgograd, Russia, Volgograd State Medical University Report Study of general toxic properties of Tenoten for children. Accumulation study (2008), Volgograd, Russia, Volgograd State Medical University Report Study of general toxic properties of Tenoten for children. Chronic toxicity study on rats (2009), Volgograd, Russia, Volgograd State Medical University Report Non-clinical safety study of Tenoten for children. Study of general toxic properties. Chronic toxicity study on infant rats, (2008), Volgograd, Russia, Volgograd State Medical University Report  Non-clinical safety study of Tenoten for children. Chronic toxicity study on rabbits, (2009), Volgograd, Russia, Volgograd State Medical University Report Non-clinical safety study of Tenoten for children. Mutagenic activity study, (2008), Volgograd, Russia, Volgograd State Medical University Report Non-clinical safety study of Tenoten for children. Reproductive toxicity study (effect of the drug on reproductive function of rats), (2008), Volgograd, Russia, Volgograd State Medical University Report Non-clinical safety study of Tenoten for children. Study of embryo- and fetotoxic effect in antenatal and postnatal development periods, (2008), Volgograd, Russia, Volgograd State Medical University Report Non-clinical safety study of Tenoten for children. Study of the effect of Tenoten for children administered to lactating females on development of their posterity, (2008), Volgograd, Russia, Volgograd State Medical University Report Non-clinical safety study of Tenoten for children. Study of allergenic and local irritating properties, (2008), Volgograd, Russia, Volgograd State Medical University
Tenoten
Tenoten® is an anti-anxiety drug with stress protective activity.
17 Researches

Tenoten

Tenoten® is an anti-anxiety drug with stress protective activity.
Information about the preparation

Report Study of antistress effects of Tenoten, P.K. Anokhin RI of Normal Physiology, RAMS, 2006  (Moscow, Russia) Report n° 06.131/5 “sample 1, sample 2, sample 3 and sample 4 evaluation for potential anxiolytic activity in the rat (p.o. administration)”, 2007 (Le Genest-Saint-Isle, France) In vitro study of ultralow doses of antibodies to S100 protein using radioligand binding assay: sigma 1 receptor, Euroscreen (г. Госсели, Бельгия) In Vitro Pharmacology: Study of Several Compounds, CEREP, 2008  (Франция) In Vitro Pharmacology: Human σ1 Receptor Binding Assay. Study of ultra-low doses of antibodies to S100 protein CEREP, 2009  (Франция) Study report Effect of Tenoten on some stress markers in rats with various stress resistance, P.K. Anokhin RI of Normal Physiology, RAMS, 2010  (Moscow, Russia) Report Non-clinical safety study of Tenoten. Acute toxicity study (Volgograd State Medical University, 2012). Report Non-clinical safety study of Tenoten. Accumulation study (Volgograd State Medical University, 2012). Report Non-clinical safety study of Tenoten. Chronic toxicity study on rats (Volgograd State Medical University, 2013). Report Non-clinical safety study of Tenoten. Chronic toxicity study on rabbits (Volgograd State Medical University, 2013). Report Non-clinical safety study of Tenoten. Mutagenic activity study (Volgograd State Medical University, 2012). Report Non-clinical safety study of Tenoten. Reproductive toxicity study: effect on reproductive function (Volgograd State Medical University, 2012). Report Non-clinical safety study of Tenoten. Study of embryo- and fetotoxic effect in antenatal and postnatal development periods (Volgograd State Medical University, 2012). Report Non-clinical safety study of Tenoten. Study of allergenic and local irritating properties (Volgograd State Medical University, 2013). Report Non-clinical safety study of Tenoten. Immunotoxicity study (Volgograd State Medical University, 2012). Report Evaluation of pharmacological activity of the drugs manufactured by OOO “NPF “Materia Medica Holding” on animal models of hypoxia (2013), Tomsk, Russia, E.D. Goldberg RI of Pharmacology, SD RAMS. Report Study of protective effect of the drugs on the model of β-amyloid amnesia in rats (2012), Saint-Petersburg, Russia, RI of Experimental Medicine, North-Western Department, RAMS.
Proproten-100
Proproten-100® is a drug to treat alcoholism.
10 Researches

Proproten-100

Proproten-100® is a drug to treat alcoholism.
Information about the preparation

Kolofort
Kolofort® is a new treatment approach for intestinal diseases.
9 Researches

Kolofort

Kolofort® is a new treatment approach for intestinal diseases.
Information about the preparation

Divaza
Divaza®: a modern-day nootropic and vasoactive drug with a novel mechanism of action intended to treat chronic cerebrovascular disorders.
17 Researches

Divaza

Divaza®: a modern-day nootropic and vasoactive drug with a novel mechanism of action intended to treat chronic cerebrovascular disorders.
Information about the preparation

Study report. Non-clinical safety study of Divaza. Study of immunotoxic properties, (2011), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of Divaza. Study of embryo- and fetotoxic effect of the drug in antenatal and postnatal development periods, (2011), Volgograd, Russia, Volgograd State Medical University. Отчет. Non-clinical safety study of Divaza. Acute toxicity study, (2011), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of Divaza. Accumulation study, (2011), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of Divaza. Study of mutagenic activity, (2011), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of Divaza. Reproductive toxicity study: effect on reproductive function, (2012), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of Divaza. Study of allergenic and local irritating properties, (2012), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of Divaza. Chronic toxicity study on rats, (2012), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical safety study of Divaza. Chronic toxicity study on rabbits, (2012), Volgograd, Russia, Volgograd State Medical University. Study report (contract 6518/12/Нак dated May 03, 2012). Study of protective effect of the drugs on the model of β-amyloid amnesia in rats, (2012), Saint-Petersburg, Russia, Research Institute of Experimental Medicine. Study report. Study of neuroprotective activity of Tenoten, Impaza and Divaza on the model of ischemic stroke induced by photothrombosis in rats, (2012), Moscow, Russia, Scientific Center of Neurology, Russian Academy of Medical Sciences. Study report. Study of anxiolytic and antidepressant effect of Divaza and Brizantin, (2012), Tomsk, RI of Pharmacology, SD RAMS. Report. Evaluation of pharmacological activity of the drugs manufactured by OOO “NPF “Materia Medica Holding” on animal models of hypoxia, (2013), Tomsk, E.D. Goldberg RI of Pharmacology, SD RAMS. Study Report. Evaluation of sample 1 using the rotarod test in the mouse (P.O. Administration), (2013), France, Porsolt & Partners Pharmacology. Study Report. Evaluation of sample 1 using the activity meter test in the mouse (P.O. Administration), (2013), France, Porsolt & Partners Pharmacology. Study Report. Evaluation of sample 1 using the beam walking test in the mouse (P.O. Administration), (2013), France, Porsolt & Partners Pharmacology. Final report. Effect of OOO "NPF "Materia Medica Holding" drugs on endothelial dysfunction in spontaneously hypertensive rats (СВX-MM002), (2014), France, Cardiomedex SAS.
Dietressa
Dietressa® is an innovative OTC drug for weight management.
14 Researches

Dietressa

Dietressa® is an innovative OTC drug for weight management.
Information about the preparation

Report Study of effect of the drug containing ultralow doses of antibodies on obesity in mice, (2008), Volgograd, Russia, Volgograd State Medical University Report Study of effect of ultralow doses of antibodies to cannabinoid receptor on weight of С57BL6mice, (2010), Volgograd, Russia, Volgograd State Medical University Report 821601 “In vitro pharmacology: human cannabinoid receptor type 1 (CB1) functional assays. Study of ultra-low doses of antibodies to cannabinoid receptor type 1”, (2011), Celle L’evescault, France, CEREP Final report Study of neurophysiologic mechanisms of narcogenic potential of the drug containing ultralow doses of antibodies, (2010), Kharkov, Ukraine, Institute of Neurology, Psychiatry and Narcology, Academy of medical sciences of Ukraine Report Non-clinical study of safety of the drug containing ultralow doses of antibodies to cannabinoid receptor. Acute toxicity study, (2010), Volgograd, Russia, Volgograd State Medical University Report Non-clinical study of safety of the drug containing ultralow doses of antibodies to cannabinoid receptor. Accumulation study, (2010), Volgograd, Russia, Volgograd State Medical University Report Non-clinical study of safety of the drug containing ultralow doses of antibodies to cannabinoid receptor. Study of mutagenic activity, (2010), Volgograd, Russia, Volgograd State Medical University Report Non-clinical study of safety of the drug containing ULD of antibodies to cannabinoid receptor. Reproductive toxicity study: effect on reproductive function of rats, (2010), Volgograd, Russia, Volgograd State Medical University Report Non-clinical study of safety of the drug containing ultralow doses of antibodies to cannabinoid receptor. Study of embryo- and fetotoxic effect of the drug in antenatal and postnatal development periods, (2010), Volgograd, Russia, Volgograd State Medical University Report Non-clinical study of safety of the drug containing ultralow doses of antibodies to cannabinoid receptor. Study of allergenic and local irritating properties, (2010), Volgograd, Russia, Volgograd State Medical University Report Non-clinical study of safety of the drug containing ultralow doses of antibodies to cannabinoid receptor. Study of immunotoxic properties, (2010), Volgograd, Russia, Volgograd State Medical University Report Non-clinical study of safety of the drug containing ultralow doses of antibodies to cannabinoid receptor. Chronic toxicity study on rabbits, (2011), Volgograd, Russia, Volgograd State Medical UniversityReport Non-clinical study of safety of the drug containing ultralow doses of antibodies to cannabinoid receptor. Chronic toxicity study on rats, (2011), Volgograd, Russia, Volgograd State Medical University Clinicaltrials
Brizantin
Brizantin® is a nicotine-free drug with a complex mechanism of action aimed at alleviating symptoms of smoking withdrawal and reducing smoking addition.
14 Researches

Brizantin

Brizantin® is a nicotine-free drug with a complex mechanism of action aimed at alleviating symptoms of smoking withdrawal and reducing smoking addition.
Information about the preparation

Final report Study of effect of Brizantin and its component (Dietressa) on tobacco addiction in rats (smoking chamber model), (2011), Kharkov, Ukraine, Institute of Neurology, Psychiatry and Narcology, Academy of Medical Sciences of Ukraine. Report Experimental study of analgesic activity of five drugs containing ULD of antibodies (hot plate), (2011), Tomsk, Russia, RI of Pharmacology, TSB SD RAMS. Study report. Study of Brizantin and its components on behaviour of mice against nicotine administration, (2011), Novosibirsk, Russia, Novosibirsk Institute of Organic Chemistry, Siberian Department, Russian Academy of Sciences. Study report. Non-clinical study of Brizantin safety. Study of allergenic and local irritating properties, (2012), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical study of Brizantin safety. Immunotoxicity study, (2012), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical study of Brizantin safety. Accumulation study, (2012), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical study of Brizantin safety. Study of mutagenic activity, (2012), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical study of Brizantin safety. Acute toxicity study, (2012), Volgograd, Russia, Volgograd State Medical University. Study report. Study of anxiolytic and antidepressant effect of Divaza and Brizantin, (2012), Tomsk, Russia, RI of Pharmacology, TSB SD RAMS. Study report. Non-clinical study of Brizantin safety. Reproductive toxicity study: effect on reproductive function, (2012), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical study of Brizantin safety. Chronic toxicity study on rabbits, (2012), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical study of Brizantin safety. Chronic toxicity study on rats, (2012), Volgograd, Russia, Volgograd State Medical University. Study report. Non-clinical study of Brizantin safety. Study of embryo- and fetotoxic effect of the drug in antenatal and postnatal development periods, (2012), Volgograd, Russia, Volgograd State Medical University. Final report Study of neurophysiologic mechanisms of narcogenic potential of low doses of antibodies, (2010), Kharkov, Ukraine, Institute of Neurology, Psychiatry and Narcology, Academy of Medical Sciences of Ukraine. (Dietressa is the component of Brizantin).
Arthrofoon
Arthrofoon® is specially designed as a long-term therapy for chronic inflammatory joint diseases, and as an aid in recovery after joint disease exacerbations.
11 Researches
Afala
Afala® is a state-of the-art drug designed to treat benign prostatic hypertrophy and chronic prostatitis.
12 Researches

Afala

Afala® is a state-of the-art drug designed to treat benign prostatic hypertrophy and chronic prostatitis.
Information about the preparation

Report Study of specific activity of homeopathic drug Anti-PSA С12+С30+С200 (2001), Tomsk, RI of Pharmacology, TSB SD RAMS. Report Experimental study of efficacy of Afala  in benign prostate hyperplasia, (2004), Tomsk, RI of Pharmacology, TSB SD RAMS. Report  Non-clinical acute toxicity study of  Afala, (2005), Tomsk, RI of Pharmacology, TSB SD RAMS. Report Non-clinical study of general toxic properties of Afala, (2005), Tomsk, RI of Pharmacology, TSB SD RAMS. Report Reproductive toxicity study of Afala, (2005), Tomsk, RI of Pharmacology, TSB SD RAMS. Report Study of potential mutagenic properties of Afala, (2005), Tomsk, RI of Pharmacology, TSB SD RAMS. Report  Experimental study of immunotoxic and allergenic properties of Afala, (2005), Tomsk, RI of Pharmacology, TSB SD RAMS. Report  Study of effect of Afala and Impaza on reproductive function of males rats, (2008), Volgograd, Volgograd State Medical University. Report Experimental study of efficacy of Impaza and Afala on the model of chronic aseptic prostate inflammation in rats, (2009), RI of Pharmacology, TSB SD RAMS, Tomsk. Different medical product samples influence on sexual behavior and erectile function in male rats (2010), Norway, Institute for Psychology, University of Tromsoe. (Report  Non-clinical study of effect of various samples of the drug on sexual behaviour and erectile dysfunction in male rats). Final Report "The Effects of Afala on the Noble Rat Model of Prostatic Inflammation" (2010), Orthotopix Ltd., Turku, Finland. (Final report Effects of Afala on prostate inflammation in Noble rats). Report  Study of accumulating properties of Afala (2012), Volgograd, Volgograd State Medical University.
Anaferon
An innovative drug for the treatment and prevention of influenza. For sale in Cambodia.
16 Researches

Anaferon

An innovative drug for the treatment and prevention of influenza. For sale in Cambodia.
Information about the preparation

Report Experimental study of Anaferon effect on humoral immune response, Tomsk, 2008 Report Experimental study of the effect of ultralow doses of antibodies to interferon-gamma on phagocytic activity of neutrophils and macrophages of peritoneal exudate, Tomsk, 2008 Report Study of efficacy of therapeutic and preventive effect of antibodies to interferon-gamma in oral administration against herpes simplex virus 2 infection in mice, Elcotes, 2002 Report Experimental study of Anaferon effect on the model of genital herpes in guinea pigs vs. acyclovir, ZPIIZ, 2006 Report Study of efficacy of therapeutic and preventive effect of antibodies to interferon-gamma in oral administration in influenza infection in mice, Bioton, 2002 Report Study of efficacy of therapeutic and preventive effect of the drug containing ultralow doses of antibodies in respiratory contamination of chicken lethal and sublethal doses of avian flu virus, Bioton, 2007 Report Study of efficacy of therapeutic and preventive effect of the drug containing ultralow doses of antibodies to human interferon-gamma in influenza infection of mice intranasally contaminated with 90% lethal dose of influenza virus (H3N2), Bioton, 2007 Report Non-clinical safety study of Anaferon. Acute toxicity study, Volgograd, 2012 Report Non-clinical safety study of Anaferon. Accumulation study, Volgograd, 2012 Report Non-clinical safety study of Anaferon. Chronic toxicity study on rats, Volgograd, 2013 Report Non-clinical safety study of Anaferon. Chronic toxicity study on rabbits, Volgograd, 2013 Report  Non-clinical safety study of Anaferon. Study of mutagenic activity, Volgograd, 2013 Report Non-clinical safety study of Anaferon. Reproductive toxicity study: effect on reproductive toxicity, Volgograd, 2013 Report Non-clinical safety study of Anaferon. Study of embryo- and fetotoxic effect of the drug in antenatal and postnatal development periods, Volgograd, 2012 Report Non-clinical safety study of Anaferon. Study of allergenic and local irritating properties, Volgograd, 2012 Clinicaltrials
Anaferon
for Children
An innovative drug for the treatment and prevention of influenza. For sale in Cambodia.
29 Researches

Anaferon for Children

An innovative drug for the treatment and prevention of influenza. For sale in Cambodia.
Information about the preparation

Final report Experimental study of specific activity of homeopathic drug “Antibodies ot human interferon-gamma (С12+С30+С50)”, Tomsk, 2001 Report Study of efficacy of therapeutic and preventive effect of antibodies to interferon-gamma in oral administration against influenza infection in mice, Bioton, 2002 Report Study of efficacy of therapeutic and preventive effect of the drug containing ultralow doses of antibodies to human interferon-gamma in influenza infection of mice intranasally contaminated with 90% lethal dose of influenza virus (H3N2), Bioton, 2007 Report "Determination of ultra-low doses of antibodies to interferon gamma antiviral efficacy after intranasal challenge with a lethal dose of influenza a virus in BALB/C mice", APcis, 2008   Report Study of efficacy of therapeutic and preventive effect of the drug containing ultralow doses of antibodies in respiratory contamination of chicken lethal and sublethal doses of avian flu virus, Bioton, 2007 Report "Antiviral efficacy of ultra-low doses of antibodies to interferon gamma in  therapy of avian influenza in JA657 chicks", APcis, 2009   Report Study of efficacy of therapeutic and preventive effect of antibodies to interferon-gamma in oral administration against herpes simplex virus 2 infection in mice, Elcotes, 2002 Report Experimental study of Anaferon effect on the model of genital herpes in guinea pigs vs. acyclovir, ZPIIZ, 2006 Report Experimental study of the effect of potentiated antibodies to interferon-gamma (С12+С30+С50), С3, С12, potentiated antibodies to erythropoietin, tumour necrosis factor-alpha on production of gamma-interferon, Tomsk, 2003 Study report Development of malignant tumours in animals by cyclophosphan and antibodies to interferon-gamma prepared using homeopathic technique, Tomsk, 2004 Acute toxicity study of Anaferon for children Report “Non-clinical safety study of Anaferon for children in sexually immature rats. Acute toxicity study. Report Non-clinical study of general toxic properties of Anaferon for children   Report Non-clinical safety study of Anaferon for children in sexually immature rats. Chronic toxicity study on sexually immature rats Report Study of potential mutagenic properties of Anaferon for children Report Reproductive toxicity study of Anaferon for children Report Non-clinical safety study of Anaferon for children in sexually immature rats. Study of Anaferon for children effect on development of infant rats when the drug was administered to lactating female rats Report Experimental study of allergenic properties of Anaferon for children Report Study of therapeutic and preventive effect of ultralow doses of antibodies to interferon-gamma in influenza infection in mice contaminated with pandemic influenza А(H1N1/09) virus, Vektor, 2009 Report Study of antiviral activity of Anaferon for children vs. Tamiflu on experimental model of swine influenza in mice contaminated with 90 and 50% lethal doses of A/H1N1 influenza virus, RI of Influenza, 2010 Report ММЕ-001 "In vitro study of ultralow doses of antibodies to interferon gamma using radioligand binding assay: effect on interferon gamma binding with interferon gamma receptor", Euroscreen, 2009 Report МММ-030-031-LAB-HIV1 "Assessment of anti-HIV-1 effects of two test articles and their combination on monocyte derived human macrophages cells and peripheral blood mononuclear cells in vitro infected with the HIV-1-BAl strain or with the HIV-1-LAI strain", APcis, 2012 Report Study of accumulating properties of Anaferon for children Report Study of antiviral activity of Anaferon for children vs. Tamiflu on experimental model of swine in mice contaminated with 90 and 50% lethal doses of A/H1N1 influenza virus, RI of Influenza, 2011 Report Study of Anaferon for children on the level of superficial expression of CD119 by immune cells ex vivo», Institute of Immunology, 2013 Determination of antiviral activity of OOO “NPF “MATERIA MEDICA HOLDING” compounds against MERS-CoV, Viroclinics Biosciences, 2015 Report № 997/11MO-01 "Efficacy of ultralow doses of antibodies to interferon gamma in therapeutic and curative therapy of influenza A viral infection in weaned Bacb/c mice", APcis, 2009 Report № UM-0217 "Antiviral efficacy of oral treatment with ООО “NPF “MATERIA MEDICA HOLDING” samples and oseltamivir in mouse model of swine influenza A/CA/04/2009 (H1N1)", Institute of Antiviral Studies, USA, 2009 «Antiviral activity determination of OOO “NPF “MATERIA MEDICA HOLDING” samples using in vitro model of rhinovirus infection in Hela cells», 2015, Imperial College, London.
Impaza
An innovative drug used for the treatment of various forms of erectile dysfunction. For sale in Cambodia.
20 Researches

Impaza

An innovative drug used for the treatment of various forms of erectile dysfunction. For sale in Cambodia.
Information about the preparation

Report “Study of a specific activity of homoeopathic drug Anti-NO-synthase C12+C30+C200, Tomsk, RI of Pharmacology, TSB SD RAMS. Report “Study of a specific activity of homoeopathic drug Anti-NO-synthetase C12+C30+C200”, (2001), Tomsk, RI of Pharmacology, TSB SD RAMS. Report “Study of ultra-low doses of antibodies to NO-synthase influences on the sexual behavior of female rats (2002), Tomsk, RI of Pharmacology, TSB SD RAMS. Report “Experimental study of mechanism of action of ultralow doses of antibodies to NO-synthase”, (2002), Tomsk, RI of Pharmacology, TSB SD RAMS. Report “Study of impaza influence on the cardiovascular system” (2002), Tomsk, RI of Pharmacology, TSB SD RAMS. Report “Single-dose toxicity study of Impaza” (2002), Tomsk, RI of Pharmacology, TSB SD RAMS. Report “Study of allergenic properties of impaza” (2003), Tomsk, RI of Pharmacology, TSB SD RAMS. Report “Study of mutagenic properties of impaza (2003), Tomsk, RI of Pharmacology, TSB SD RAMS. Report “Reproductive toxicity study of Impaza” (2003), Tomsk, RI of Pharmacology, TSB SD RAMS. Report “Non-clinical study of general toxic properties of Impaza (2003), Tomsk, RI of Pharmacology, TSB SD RAMS. Sexual behavior and erectile function in old rats: the influence of 4-week treatment (2006), Norway, Institute for Psychology, University of Tromsoe.   Sexual behaviour and erectile function in mature rats with reduced erectile function: The influence of 4-week treatment (2007), Norway, Institute for Psychology, University of Tromsoe. Study report “Study of the psychotropic effects of impaza in rats” (2007), Tomsk, RI of Pharmacology, TSB SD RAMS. Report “Study of the effect of Afala and Impaza on generative function in male rats” (2008), Volgograd, Volgograd State Medical University Report on the study Study of Impaza influence on liver function in male rats (“hexenalum induced sleep” test) (2008), Volgograd, Volgograd State Medical University Report on experimental studies titled “The study of the efficacy of Impaza and afala in prostate chronic aseptic inflammation in rats” (2009), Tomsk, RI of Pharmacology, TSB SD RAMS. Different medical product samples influence on sexual behavior and erectile function in male rats (2009), Norway, Institute for Psychology, University of Tromsoe. Report on the study “Study of impaza cumulative toxicity” (2012), Volgograd, Volgograd State Medical University Report on the study “Study of impaza immunotoxic properties” (2012),  Volgograd, Volgograd State Medical University Effect of OOO "NPF "Materia Medica Holding" drugs on endothelial dysfunction in spontaneously hypertensive rats (2014) Cardiomedex, France